Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0722.1972.tb00288.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Henri Coutard (1876-1950): A Pioneer of Fractionated Radiotherapy Regimens.
Cureus
September 2024
Nuclear Medicine, Tata Main Hospital, Jamshedpur, IND.
Henri Coutard was a prominent French roentgen therapist (radiation therapist). He was a pioneer physician and scientist who established the development of the "protracted-fractional method" of radiation dosing. He treated laryngeal cancer with super-voltage x-rays and also published data on five-year survival rates while his contemporary physicians indulged in treating cancer with radioactive sources.
View Article and Find Full Text PDFQuantitative Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following Lu-PSMA-617 (VISION Trial).
Radiology
August 2024
From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.).
Article Synopsis
- Lutetium 177 (Lu-PSMA-617) is a targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), and baseline Ga-PSMA-11 PET/CT parameters may help determine treatment effectiveness.
- The analysis used data from the VISION trial, where participants received either Lu-PSMA-617 plus standard care or standard care alone, focusing on how various PET parameters related to treatment outcomes like survival and response rates.
- Results showed that higher whole-body tumor standardized uptake value (SUV) was linked to better treatment outcomes; for every 1-unit increase in SUV, the risk of radiographic progression and death decreased, indicating Lu-PS
Incidence and survival of secondary malignancies after external beam radiotherapy for prostate cancer in the SEER database.
Can Urol Assoc J
April 2024
Division of Radiation Oncology, BC Cancer, Vancouver, BC, Canada.
Introduction: We investigated the incidence of secondary bladder (BCa) and rectal cancers (RCa) after external beam radiotherapy (EBRT) for prostate cancer (PCa) compared to radical prostatectomy (RP) alone, and compared cancer-specific survival (CSS) of these secondary neoplasms to their primary counterparts.
Methods: This retrospective cohort study included men in the SEER cancer registry with a diagnosis of non-metastatic, clinically node-negative PCa treated with either RP or EBRT from 1995-2011 and allowed a minimum five-year lag period for the development of secondary BCa or RCa. Patients were divided into two eras, 1995-2002 and 2003-2011, to examine differences in incidence of secondary malignancies over time.
Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment.
Heliyon
January 2024
Department of Orthopedics, Yixing People's Hospital, Yixing, China.
Esophageal cancer (EC) is a common and devastating tumor of the upper digestive tract. Unfortunately, by the time any symptoms have manifested, the disease has often progressed to an advanced stage and is accompanied by macro- and micrometastases, including in the bones. The treatment of esophageal cancer with bone metastases remains clinically challenging, given the poor prognosis associated with this condition.
View Article and Find Full Text PDFProtective effects of exogenous melatonin therapy against oxidative stress to male reproductive tissue caused by anti-cancer chemical and radiation therapy: a systematic review and meta-analysis of animal studies.
Front Endocrinol (Lausanne)
September 2023
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Male testicular dysfunction is a considerable complication of anti-cancer therapies, including chemotherapy and radiotherapy, partly due to the increased oxidative stress caused by these treatments. Melatonin is an effective antioxidant agent that protects testicles against physical and toxic chemical stressors in animal models. This study aims to systematically review the melatonin's protective effects against anti-cancer stressors on rodential testicular tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!